At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 22, 2026 at 16:15 ET
Dyne Therapeutics elected Barry E. Greene as an independent Class I director to its board. This is a routine board appointment with standard compensation under the non-employee director program, no material financial or strategic impact.
- Barry E. Greene elected as Class I director effective June 22, 2026
- Not appointed to any board committees
- Received option to purchase 57,463 shares at $20.87 per share, vesting over 3 years
- Annual cash compensation of $45,000 as board member
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access